

09.00 **Registration & Refreshments**

09.45 **Chair's Opening Remarks** - *Alastair McLellan*, Editor, HSJ

10.00 **Opening Keynote Plenary**

Lord O'Shaughnessy, Parliamentary Under Secretary of State,
Department of Health and Social Care

10.30 **Panel Discussion: What the NHS 10-year plan means for industry**

Erik Nordkamp, Managing Director, Pfizer UK

Dr Sam Roberts, Director of Innovation, Research and Life Sciences Group, NHS England

Mike Thompson, Chief Executive, ABPI

11.15 **Morning Refreshments & Networking**

11.30 **Academic Health Science Networks: Enabling joint-working across whole healthcare systems**

- Hear specific case studies of how AHSNs have helped industry develop joint-working relationships with STPs and ICSs
- Find out how AHSNs have supported full data sharing to aid industry collaboration
- Understand how innovative digital technology has been implemented through AHSNs to improve patient outcomes

12.30 **Networking Lunch**

13.30 **GOVERNANCE & REGULATION**

Adopting innovation: success stories from Accelerated Access Collaborative

- Find out how the Accelerated Access Collaborative has performed so far
- Hear how it has sped up access and aided innovation for new products
- How can the AAC become more beneficial for industry and what barriers remain?

Innovation & Digital

Using data to support innovation

- Learn how Local Health and Care Records (LHCRE) are being used in regional hubs
- Find out how new digital technologies will be evaluated in future
- Gain insight into how data flows are being utilised and what rules are being enforced

NHS Landscape

Understanding industry's role in STPs and ICSs

- Hear first hand the plans being created at a local level through the STP process
- Learn what challenges STPs are facing and how industry could support
- Take part in a discussion to find out how industry can better support STPs



14.20 **SESSION CHANGE**

14.25 **GOVERNANCE & REGULATION**

Removing barriers: evolving the role of regulation

- Understand how the role of MHRA is changing and what this means for industry
- Learn about the successes from the NICE fast track programme
- Find out how NHS England's commercial team has improved access to new drugs

Meindert Boysen, Centre for Health Technology Evaluation Director, NICE

Blake Dark, NHS Commercial Medicines Director, NHS England

Dr Ian Hudson, Chief Executive, MHRA

Innovation & Digital

Unleashing the potential of genomics and personalised medicine

- Receive an update on 100,000 Genomes project
- How the is project making the UK an attractive investment destination for life sciences
- Learn how data is being used to accelerate treatments and enable efficient drug research

Joanne Hackett, Chief Commercial Officer, Genomics England

NHS Landscape

Specialised Commissioning: Improving access to new treatments in rare diseases

- Gain insight into progress made by the UK strategy for rare diseases
- Understand NHS England's approach to specialised commissioning of medicines

Joanne Hackett, Chief Commercial Officer, Genomics England

15.15 **Afternoon Refreshments & Networking**

15.30 **PPRS: What the final agreement means for industry and the NHS**

Steve Oldfield, Chief Commercial Officer, Department of Health and Social Care

16:00 **Panel Discussion:**

Next steps for implementing the Life Sciences Industrial Strategy in post-Brexit Britain

Sir John Bell, Regius Professor of Medicine, University of Oxford

Tamsin Berry, Deputy Director, Office for Life Sciences

Tunde Falude, Managing Director, Sanofi

Nicole Mather, Director, Life Sciences and Healthcare, Deloitte

16.45 **Chair's Closing Remarks - Alastair McLellan**, Editor, HSJ

17.00 **Networking Reception**



**BOOK
TICKETS**